Effect of Sanhuang Yishen Capsule and Smeaglutide Injection on Serum C1q Tumor Necrosis Factor Related Protein in diabetes Nephropathy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400079569

Enrollment

Unknown

Registered

2024-01-06

Start date

2024-02-02

Completion date

Unknown

Last updated

2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Nephropathy

Interventions

Intervention group of Smegglutide Injection:Smegglutide Injection

San Huang Yi Shen Capsules+Smegglutide Injection Intervention Group:Sanhuang Yishen Capsules+Smegglutide Injection

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Those who meet the diagnostic criteria of T2DM and DKD in western medicine, the glomerular filtration rate of diabetes nephropathy is more than 60ml/(min. 1.73m2), and the urinary albumin/creatinine (ACR) is 30-300mg/g, and meet the syndrome differentiation criteria of deficiency of both qi and yin and blood stasis in Chinese medicine. 2. The age range is between 18 and 65 years old, regardless of gender. 3. BMI between 24-28 kg/m2 (including both ends). 4. Take sufficient oral doses of metformin tablets and another oral hypoglycemic drug to reach the maximum or maximum tolerable dose, and maintain a stable dose for at least 8 weeks, with glycated hemoglobin between 7-8% (including both ends). 5. Informed consent and voluntary participation in the trial.

Exclusion criteria

Exclusion criteria: 1. Patients with severe heart, liver, and kidney dysfunction, malignant tumors, or other serious diseases of various systems. 2. diabetes complicated with acute complications (ketoacidosis, electrolyte disorder, infection, hypertonic state) and serious chronic complications (diabetes retinopathy = grade 4, diabetes foot). 3. Hypertensive patients or individuals using ACEI or ARB drugs. 4. Abnormal blood lipids 5. Mental illness patients and pregnant or lactating women. 6. Those who do not sign the informed consent form. 7. Allergic constitution or history of multiple drug allergies. 8. Patients with a personal or family history of medullary thyroid carcinoma (MTC), or type 2 multiple endocrine tumor syndrome (MEN-2). 9. Patients who are participating in clinical trials of other drugs.

Design outcomes

Primary

Measure	Time frame
glycosylated hemoglobin;Urinary microalbumin/creatinine;Fasting blood glucose;Two hours post meal blood sugar;Body weight;	—

Secondary

Measure	Time frame
Serum c1q tumor necrosis factor related protein;	—

Countries

China

Contacts

Public ContactCui ronggang

Hebei Cangzhou Integrated Traditional Chinese and Western Medicine Hospital

cuirgdujx1215@sina.com+86 180 3178 3391

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026